Welcome to our dedicated page for Acadia Healthcar news (Ticker: ACHC), a resource for investors and traders seeking the latest updates and insights on Acadia Healthcar stock.
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) is a behavioral healthcare company that operates a large network of inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, comprehensive treatment centers and outpatient clinics across the United States and Puerto Rico. This news page aggregates company-specific updates and disclosures that help investors and observers follow developments in Acadia’s behavioral healthcare operations and corporate activities.
News related to ACHC often includes quarterly earnings releases, updates to financial guidance, and details on revenue performance by service type, such as acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers and residential treatment centers. The company also issues news about capital expenditure plans, bed additions, and development activity, including the opening of new hospitals, expansions of existing facilities and the addition of new comprehensive treatment centers.
Acadia’s news flow features announcements about participation in healthcare and investor conferences hosted by firms such as J.P. Morgan, UBS and Jefferies, where members of senior management discuss strategy, capital allocation and operating performance. Press releases may also cover executive leadership changes, including appointments and transitions in key roles like the Chief Financial Officer and Chief Operating Officer, as well as statements from the company regarding its approach to shareholder value and governance.
Other notable news items can include updates on professional and general liability reserves, securities litigation settlements, and responses to public letters from shareholders who comment on strategy and governance. By reviewing the ACHC news feed on this page, users can monitor Acadia’s reported operating trends, strategic priorities, capital plans and governance developments over time.
Acadia Healthcare has launched four new Comprehensive Treatment Centers (CTCs) in Georgia, enhancing its outpatient care services for adults dealing with opioid addiction. The facilities provide medication-assisted treatment (MAT) and therapy to support recovery, following the recent acquisition from Brand New Start Treatment Centers. Located in Cumming, Loganville, Dallas, and Woodstock, the CTCs aim to combat the opioid epidemic, operating Monday-Saturday with comprehensive care options. Acadia remains a leader in behavioral healthcare, managing 242 facilities across the U.S.
Acadia Healthcare (NASDAQ: ACHC) has acquired four comprehensive treatment centers (CTC) from Brand New Start Treatment Centers in the Atlanta area, expanding its CTC network to 148 facilities. This acquisition aims to bolster its medication-assisted treatment (MAT) programs, essential in addressing the growing opioid crisis. The CEO, Chris Hunter, emphasized the centers' operational success and potential for positive patient outcomes. Acadia currently operates 242 behavioral healthcare facilities across the U.S., serving about 70,000 patients daily.
Acadia Healthcare Company (NASDAQ: ACHC) will participate in the Credit Suisse 31st Annual Healthcare Conference from November 7-10, 2022, at Terranea Resort, Rancho Palos Verdes, California. The company's presentation will be webcast live from their website on November 8, 2022, starting at 10:25 a.m. Pacific Time. A replay will be available for 30 days. Acadia operates 242 behavioral healthcare facilities with approximately 10,800 beds across 39 states and Puerto Rico, serving about 70,000 patients daily.
Acadia Healthcare Company (NASDAQ: ACHC) reported a 13.5% increase in revenue, totaling $666.7 million for Q3 2022, compared to the same quarter last year. Same-facility revenue rose 10.2%, driven by a 6.9% increase in revenue per patient day. Net income was $71.1 million ($0.78 per share), and adjusted EBITDA reached $162.8 million. The company opened new facilities, including a children's hospital in Chicago, and continues to expand its service offerings. Financial guidance for 2022 is narrowed, estimating revenue between $2.58 billion and $2.60 billion.
Summary not available.
Acadia Healthcare Company (NASDAQ: ACHC) will release its Q3 2022 results on October 31, 2022, post-market. A conference call for institutional investors and analysts is scheduled for 9:00 a.m. ET on November 1, 2022. As of June 30, 2022, Acadia operates 239 facilities across the U.S. and Puerto Rico, providing services to approximately 70,000 patients daily. The company is the largest stand-alone behavioral health provider in the U.S., with over 22,500 employees and about 10,600 beds available.
On September 27, Acadia Healthcare and Henry Ford Health commenced construction on a new behavioral health facility in West Bloomfield, Michigan, expected to open in 2024. The hospital will span 120,000 square feet with an initial capacity of 184 inpatient beds, expandable to 192. This collaboration aims to address the surge in mental health needs exacerbated by the COVID-19 pandemic. The facility will also serve as an academic site, training future behavioral health providers.
Acadia Healthcare (NASDAQ: ACHC) has formalized an affiliation with Thomas Jefferson University in Philadelphia to enhance behavioral healthcare training and clinical care. This partnership will make Belmont Behavioral Health Hospital a primary teaching site for Jefferson's psychiatric residents and students. The collaboration aims to integrate behavioral and medical care, improve clinical outcomes, and develop new programs to meet the rising demand for behavioral healthcare services. Acadia operates 239 facilities across the U.S., serving around 70,000 patients daily.
Acadia Healthcare Company has appointed Dr. Nasser Khan, M.D., as the Operations Group President for its Comprehensive Treatment Center (CTC) business, effective September 6th. Dr. Khan will manage Acadia’s 145 CTC facilities, focusing on enhancing patient care amid the opioid crisis. He previously held senior roles at Shields Health Solutions and Biograph Inc. Dr. Khan aims to improve clinical outcomes and expand services to communities affected by addiction.
Acadia Healthcare (NASDAQ: ACHC) announced that select facilities will participate in a trial studying suicidal ideation and behavior in major depression, sponsored by Seelos Therapeutics (NASDAQ: SEEL) for the SLS-002 drug. This drug, an intranasal ketamine, aims to address an unmet need for treating these conditions. The trial includes a five-dose treatment regimen over 15 days. Acadia's involvement underscores its mission to deliver innovative care, with promising preliminary results for SLS-002.